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Objectives This study evaluated data from 3 federally funded trials that focused on optimal medical therapy to determine if
formalized attempts at risk factor control within clinical trials are effective in achieving guideline-driven treat-
ment goals for diabetic patients with coronary artery disease (CAD).
Background Despite clear evidence of benefit for CAD secondary prevention, the level of risk factor control in clinical practice
has been disappointing.
Methods We obtained data from the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evalua-
tion) diabetes subgroup, (n  766 of 2,287), the BARI 2D (Bypass Angioplasty Revascularization Investigation 2
Diabetes) trial (n  2,368), and the FREEDOM (Comparison of Two Treatments for Multivessel Coronary Artery
Disease in Individuals With Diabetes) trial (n  1,900) to evaluate the proportion of patients achieving guideline-
based, protocol-driven treatment targets for systolic blood pressure, low-density lipoprotein cholesterol, smoking
cessation, and hemoglobin A1c. The primary outcome measure was the proportion of diabetic CAD patients
meeting all 4 pre-specified targets at 1 year after enrollment.
Results The pooled data include 5,034 diabetic patients. The percentages of patients achieving the 1-year low-density
lipoprotein cholesterol targets compared with baseline increased from 55% to 77% in COURAGE, from 59% to
75% in BARI 2D, and from 34% to 42% in FREEDOM. Although similar improved trends were seen for systolic
blood pressure, glycemic control, and smoking cessation, only 18% of the COURAGE diabetes subgroup, 23% of
BARI 2D patients, and 8% of FREEDOM patients met all 4 pre-specified treatment targets at 1 year of follow-up.
Conclusions A significant proportion of diabetic CAD patients fail to achieve pre-specified targets for 4 major modifiable car-
diovascular risk factors in clinical trials. We conclude that fundamentally new thinking is needed to explore ap-
proaches to achieve optimal secondary prevention treatment goals. (Clinical Outcomes Utilizing Revasculariza-
tion and Aggressive Drug Evaluation; NCT00007657) (Bypass Angioplasty Revascularization Investigation 2
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Risk Factor Control for CAD April 16, 2013:1607–15Coronary artery disease (CAD)
is the leading cause of death and
disability worldwide and is par-
ticularly prevalent among popu-
lations with diabetes and hyper-
tension (1). Significant advances
in revascularization techniques
for the treatment of CAD have
been accompanied by concomi-
tant improvements in medical
management over the past 2 de-
cades. In general, contemporary
optimal medical therapy (OMT)
includes lifestyle interventions
(heart-healthy diet, weight loss/
maintenance, regular exercise,
smoking cessation) and multifaceted pharmacotherapy
aimed at controlling hyperlipidemia, hypertension, and
diabetes mellitus (DM). Based on scientific evidence that
the control of multiple cardiovascular risk factors reduces
cardiovascular events (2), clinical practice guidelines have
been established and disseminated broadly. These include
guidelines from the Adult Treatment Panel III, the Seventh
Report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pres-
sure, the American Diabetes Association, the American
College of Cardiology, and the American Heart Association
(3–6). Current Adult Treatment Panel III guidelines advo-
cate a low-density lipoprotein cholesterol (LDL-C) goal of
100 mg/dl in patients with established CAD (3), with a
more aggressive LDL-C goal of 70 mg/dl suggested for
high-risk patients (7). In the Seventh Report of the Joint
National Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure, the target blood
pressure goal is 140/90 mm Hg in nondiabetic patients and
130/80 mm Hg in diabetic patients (4). Although the data
or the reduction in cardiovascular events with glycemic
ontrol based on hemoglobin A1c (HbA1c) is controver-
ial, the American Diabetes Association guidelines for
iabetes management recommend a reasonable HbA1c
oal of 7% (5,8). Finally, the updated American Col-
ege of Cardiology/American Heart Association guide-
ines on secondary prevention and risk reduction in CAD
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Abbreviations
and Acronyms
CAD  coronary artery
disease
DM  diabetes mellitus
HbA1c  hemoglobin A1c
LDL-C  low-density
lipoprotein cholesterol
OMT  optimal medical
therapy
PCI  percutaneous
coronary intervention
SBP  systolic blood
pressurea
Manuscript received October 25, 2012; revised manuscript received January 3,
2013, accepted January 8, 2013.atients advocate active physician intervention and coun-
eling for patients to quit smoking with an ultimate goal
f complete tobacco cessation (6).
Thus, control of these 4 risk factors is associated with
mproved clinical outcomes and is the foundation of OMT
or patients with CAD, regardless of whether patients
ndergo coronary revascularization (either percutaneous
oronary intervention [PCI] or coronary artery bypass graft
urgery) (2). Nevertheless, it has been documented that it is
ifficult to achieve risk factor control in routine clinical
ractice (9,10). Whether achievement of pre-specified treat-
ent targets could be facilitated by a carefully designed,
igorous, and purposeful approach is unknown. For this
eason, we hypothesized that protocol-driven risk factor
eduction in major randomized trials may provide an effec-
ive platform for risk factor control. Accordingly, we exam-
ned the results in attaining secondary prevention targets
mong CAD patients with DM who were randomized from
he COURAGE (Clinical Outcomes Utilizing Revascular-
zation and Aggressive Drug Evaluation) (11,12), BARI 2D
Bypass Angioplasty Revascularization Investigation 2 Di-
betes) (13), and FREEDOM (Comparison of Two Treat-
ents for Multivessel Coronary Artery Disease in Individ-
als With Diabetes) (14) trials.
ethods
he principal investigators of 3 federally funded clinical
rials involving coronary revascularization and OMT were
pproached and agreed to participate in a collaborative
nalysis to ascertain the degree to which pre-defined,
rial-specific treatment targets for CAD risk factors were
chieved between baseline and the 1-year follow-up. All 3
rials recognized the critical importance of risk factor
ontrol by establishing predetermined treatment targets for
MT. In general, OMT consisted of vascular disease-
odifying interventions (aspirin, statins, inhibitors of the
enin-angiotensin system, and thienopyridines as needed),
herapeutic agents to control angina and myocardial isch-
mia (beta-blockers, calcium channel blockers, long-acting
itrates), and aggressive lifestyle interventions (nutrition
ounseling, weight loss, exercise, smoking cessation). The
nited States Veterans Affairs and Canadian Institutes of
ealth Research-funded COURAGE trial randomized
,287 stable CAD patients from 1999 through 2004,
omparing OMT with and without PCI; of note, 766
atients (34%) had DM. The nondiabetic patients in the
OURAGE trial were the comparator group for the
iabetic cohorts because the other trials enrolled only
atients with diabetes. The National Heart, Lung, and
lood Institute–sponsored BARI 2D trial randomized
,368 angiographically documented CAD patients with
ype II DM from 2001 through 2005 to either prompt
evascularization (either PCI or coronary artery bypass graft,
s decided by the patient’s physician) with OMT, or OMT
lone. Finally, in the National Heart, Lung, and Blood
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April 16, 2013:1607–15 Risk Factor Control for CADInstitute–sponsored FREEDOM trial, 1,900 diabetic pa-
tients with multivessel CAD were randomized from 2005
through 2010 to either PCI with drug-eluting stents or
coronary artery bypass graft surgery. In this study, OMT
was prescribed to the overall population, but the control of
risk factors was relegated to community physicians. Overall,
great effort was taken in all 3 trials to communicate with
study centers and to develop strategies to enhance the
achievement of risk factor goals. These protocols were
described previously in detail (14–16). All 3 studies used
feedback mechanisms and tracking programs to ensure that
investigators were in constant communication with provid-
ers at the local sites to foster attainment of goals, especially
when goals were not being achieved. The COURAGE and
BARI 2D trials additionally used a case-managed approach
with nurse practitioners or study coordinators organizing
intensive, individualized protocol-driven care through
multiple visits and close follow-up. All 3 trials were
approved by the institutional review boards of all partic-
ipating institutions.
Data were provided by the individual trial steering com-
mittees, which included baseline characteristics, medication
use, and achievement of pre-specified treatment targets for
LDL-C, systolic blood pressure (SBP), HbA1c, and smok-
ing cessation. Medications ascertained included antiplatelet
agents, lipid-lowering agents, and antihypertensive agents
such as calcium-channel blockers, angiotensin II-converting
enzyme inhibitors, angiotensin receptor blockers, and beta-
blockers. Laboratory and clinical parameters analyzed in-
cluded LDL-C, SBP, HbA1c (for DM patients), and
percentage of smokers. Data were recorded from each trial
in a uniform format, and data summaries from individual
trials were checked against the associated publications for
accuracy.
Statistical analysis. We compared diabetic patients among
he COURAGE, BARI 2D, and FREEDOM trials and
sed the COURAGE nondiabetic cohort as a comparator
roup. Data were analyzed to calculate the proportion of
atients meeting each pre-specified treatment target. Pa-
ients meeting all 4 targets were defined as nonsmokers who
et the goal for LDL-C, SBP, and HbA1c (for DM
Comparison of SecondaryPrevent on Risk Factor Targets by TrialTable 1 Comparison of Seconda yPrevention Risk Factor Targets by Trial
Target COURAGE NDM COURAGE DM BARI 2D FREEDOM
LDL-C (mg/dl) 100 100 100 70
SBP (mm Hg) 130 130 130 130
HbA1c (%) — 7.0 7.0 7.0
Smoking (%) 0 0 0 0
Targets reported for this analysis using the pertinent contemporary guideline of the time.
BARI 2D Bypass Angioplasty Revascularization Investigation 2 Diabetes; COURAGE Clinical
utcomes Utilizing Revascularization and Aggressive Drug Evaluation; DM  diabetes mellitus;
REEDOM Comparison of Two Treatments for Multivessel Coronary Artery Disease in Individuals
ith Diabetes; HbA1c  hemoglobin A1c; LDL-C  low-density lipoprotein cholesterol; NDM 
ondiabetes mellitus; SBP  systolic blood pressure.atients) as defined by each respective trial (Table 1). Allavailable data at each time point (baseline and 1 year) were
used in the analyses.
Results
The pooled data for the population under study comprised
5,034 diabetic patients with CAD. Despite the different
study designs, the baseline characteristics of the enrolled
patients generally were similar across the trials (Table 2). In
all 3 trials, use of proven secondary prevention therapies
increased between baseline and the 1-year follow-up (Table 3).
Table 4 demonstrates that the mean values of attained risk
factor goals across the trial populations at 1 year of
follow-up decreased to levels within, or close to, targets as
pre-specified by each respective trial.
Low-density lipoprotein cholesterol. In the COURAGE
nondiabetic group, 46% of patients achieved the LDL-C
goal of100 mg/dl at baseline (Table 5) (Fig. 1). At 1 year,
this improved to 74%. Similarly in the COURAGE trial
DM patients, 55% met the LDL-C target at baseline,
which improved to 77% at 1 year. The percentage of
patients meeting LDL-C goals increased similarly in the
BARI 2D trial, improving from 59% to 75% at 1 year.
Given the evolution of guideline standards, a more stringent
target of 70 mg/dl was used in the FREEDOM trial. At
1 year, only 42% of patients met this goal, improving from
a baseline of 34%. However, for comparative purposes across
all studies, we note that 62% of FREEDOM patients had an
LDL-C of 100 mg/dl at baseline and 75% achieved the
LDL-C goal of100 mg/dl at 1 year. Thus, for all 3 trials, the
percentage of diabetic patients with CAD who attained an
LDL-C of 100 mg/dl at 1 year ranged from 75% to 77%.
Systolic blood pressure. All 3 trials used an SBP target of
130 mm Hg in both patients with and without DM.
Nondiabetic patients in the COURAGE trial fared better,
improving from 46% to 60% meeting the target after 1 year
(Table 5) (Fig. 2). Conversely, the SBP target in diabetic
patients in the COURAGE trial improved from a baseline
of 37% to only 49%, whereas in the BARI 2D trial, with
exclusively diabetic patients, the percentage of patients who
achieved their target SBP goal increased from 49% to 56%.
In the FREEDOM trial, the percentage of patients who
achieved the SBP goal decreased slightly from 40% to 38%
at 1 year. In all 3 studies, more than 80% of patients were
taking a beta-blocker at 1 year, with most patients taking at
least 1 antihypertensive medication. As was found with
LDL-C, mean values for blood pressure targets seemed
favorable, but one-quarter to two-thirds of subjects had SBP
values higher than the trial-specified target at 1 year.
Glycemic control. Approximately one-half of diabetic pa-
tients in all 3 trials did not achieve an HbA1c level of 7%
at 1 year (Table 5) (Fig. 3). There was little evidence of
improved glycemic control in the diabetic group in the
COURAGE trial at 1 year, decreasing from 50% to 48% of
those achieving the target HbA1c. In the BARI 2D trial,
the 1-year glycemic control rate was 51%, a substantial
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Risk Factor Control for CAD April 16, 2013:1607–15increase from the 40% of patients meeting the HbA1c target
at baseline. In the FREEDOM trial, 45% of diabetic CAD
patients met the HbA1c goal at 1 year, increasing from 37%
at baseline.
Smoking cessation. In the COURAGE trial, nondiabetic
atients who were nonsmokers increased from 69% at
aseline to 77% at 1 year. Among COURAGE DM
atients, the rate of nonsmokers improved from 76% at
aseline to 86% at 1 year. In the BARI 2D trial, 88% met
he target at baseline and 90% met the target at 1 year,
hereas in the FREEDOM trial, 84% were not smoking at
aseline, which increased to 94% at 1 year.
roportion of CAD patients with DM achieving all 4
reatment targets. Given the inherent difficulty in control-
ing individual risk factors, it is perhaps not surprising that
o trial achieved more than 25% of their diabetic patients
ho were able to achieve the trial-specified composite
argets for all 4 major risk factor targets (LDL-C, SBP,
bA1c, and smoking cessation) (Table 5) (Fig. 4). In the
COURAGE nondiabetic group, 46% achieved all 3 targets
(no HbA1c target for nondiabetic patients) at 1 year,
compared with 16% at baseline. By contrast, only 18% of
the diabetic subgroup achieved all 4 treatment targets at 1
year compared with 7% at baseline. In the BARI 2D trial,
23% of patients reached all 4 targets at 1 year, compared
with 14% at baseline. With the more stringent LDL-C
target of 70 mg/dl in the FREEDOM trial, only 8% of
Baseline Patient Characteristics of the 3 TrialsTable 2 Baseline Patient Characteristics of
COURAGE NDM
(n  1,482)
Mean age (yrs) 62.0
Female (%) 15
Ethnic minority* (%) 11
Angina (%) 88
Prior MI (%) 40
Prior PCI (%) 14
Prior CABG (%) 10
Heart failure history (%) 3
Stroke/TIA (%) 7
PAD (%) 6
*Non-Caucasian white.
CABG  coronary artery bypass graft; MI  myocardial Infarction; P
TIA  transient ischemic attack. Other abbreviations as in Table 1.
Proportion Prescribed Each Medication in the 3 Trials at 1 YearTable 3 Proportion Prescribed Each Medication in the 3 Trials
COURAGE NDM COURAG
Baseline
(n  1,236)
1 Year
(n  1,366)
Baseline
(n  589)
Lipid lowering (%) 70 97 71
Statins (%) 67 95 67
ACEI/ARB (%) 46 66 65
Beta-blocker (%) 72 85 70
CCB (%) 29 43 33
Aspirin (%) 87 96 88ACEI/ARB  angiotensin II-converting enzyme inhibitor/angiotensin II receptor blocker; CCB  calcium cpatients met all 4 major goals at 1 year, compared with 4%
at baseline.
Discussion
The principal finding of this collaborative analysis of data
from 5,034 diabetic patients with CAD enrolled in the
COURAGE, BARI 2D, and FREEDOM trials is that the
percentage of patients who simultaneously achieved pre-
specified treatment goals for LDL-C, SBP, HbA1c, and
smoking cessation 1 year after randomization was low,
ranging from 8% to 23%. This finding is disappointing in
the context of randomized clinical trials, in which highly
competent teams of multidisciplinary healthcare providers
with specialized training interacted with patients in a
clinical trial setting that created a clinical care environment
where risk factor management was facilitated. The reasons
for the limited success in achieving risk factor control for all
4 risk factors in diabetic patients with CAD may be related
to complex interactions of the patients’ disease burden, their
lifestyle behavior, the medical team, and their underlying
socioeconomic environment.
When compared with the proportion of patients having
all 4 risk factors under control, the percentage of patients
meeting individual targets was higher. For instance,
LDL-C of100 mg/dl was observed in approximately 75%
of diabetic patients, and the SBP goal of 130/80 mm Hg
Trials
RAGE DM
 766)
BARI 2D
(n  2,368)
FREEDOM
(n  1,900)
62.4 62.4 63.1
14 30 29
21 34 49
88 82 86
37 32 26
18 20 1.2
13 6 0
8 7 27
10 10 3
11 24 11
peripheral artery disease; PCI  percutaneous coronary intervention;
Year
BARI 2D FREEDOM
ear
674)
Baseline
(n  2,368)
1 Year
(n  2,142)
Baseline
(n  1,900) 1 Year
6 79 98 86 94
3 75 94 82 90
4 77 90 78 80
0 73 86 75 82
7 10 9 32 23
4 88 92 91 96the 3
COU
(nat 1
E DM
1 Y
(n 
9
9
8
9
4
9hannel blocker; other abbreviations as in Table 1.
1611JACC Vol. 61, No. 15, 2013 Farkouh et al.
April 16, 2013:1607–15 Risk Factor Control for CADranged from 38% to 56% at 1 year. The achievement of
individual goals in this study of high-risk patients was better
than has been reported for the general diabetic population
(17–19).
Numerous factors likely contributed to the limited success
in achieving composite risk-factor goals in these 3 trials.
Among the potential contributors is a lack of physician
compliance with evidence-based American College of Car-
diology/American Heart Association management guide-
lines (6,20), although the extent to which this adversely
impacted risk factor control in these studies was not
examined specifically. However, investigators in the 3 trials
communicated frequently with the community physicians
caring for the patients with newsletters, educational mate-
rials, and other communications to increase the likelihood
that appropriate medications at appropriate doses would be
prescribed to achieve secondary prevention goals.
Another difficulty in achieving multiple risk-factor goals
is the inherent challenge of medication regimen adherence
by patients. In routine practice, medication prescriptions
often are not filled or continued long-term. Barriers may
include cost, the burden of taking multiple medications,
drug-drug interactions, and side effects (21). The complex
problem of limited patient adherence is underscored by
the heterogeneity of compliance improvement when cost
is removed as a factor. A recent trial indicated that
patient adherence rates after a myocardial infarction
improved only marginally if the medications were pro-
vided free of charge (22).
Even if medications are prescribed and prescriptions
are filled, patient nonadherence remains a problem.
Among factors that may modulate patient adherence are
Mean Values for Cardiovascular Risk Factors at Baseline and 1 YeTable 4 Mean Values for Cardiovascular Risk Factors at Baseli
COURAGE NDM COURAGE D
Risk Factor
Baseline
(n  1,482)
1 Year
(n  1,366)
Baseline
(n  766) (
LDL-C (mg/dl) 107 34 86 27 101 27
SBP (mm Hg) 131 19 125 17 135 17 1
HbA1c (%) 5.5 0.6 — 7.2 1.6
Smoking (%) 31 (29–33) 23 (21–26) 24 (21–27) 1
Values are mean  SD or % (95% confidence interval).
Abbreviations as in Table 1.
Proportion of Patients Meeting Targets in the 3 Trials Over 1 YearTable 5 Proportion of Patients Meeting Targets in the 3 Trials
Risk Factor
COURAGE NDM COURAGE
Baseline
(n  1,478)
1 Year
(n  1,367)
Baseline
(n  762)
LDL-C (%) 46 74 55
SBP (%) 46 60 37
HbA1c (%) — — 50
Nonsmoking (%) 69 77 76
Met All 4 goals 16 46 7Targets were defined as follows (see Table 1): LDL-C: 100 mg/dl (except for FREEDOM, with LDL-C 7
Abbreviations as in Table 1.advanced age, comorbid conditions, complexity of treat-
ment regimen, health beliefs, healthcare setting, socio-
economic status, social support, and psychological state
(21,23). These and other factors may result in patients
deciding on their own to avoid adhering to risk factor
modification regimens.
Among patients with chronic disease states, such as
diabetic patients with CAD, more than 50% show poor
adherence to treatment and fewer than 30% follow the
recommended lifestyle modifications (24). Underscoring the
importance of adherence to patient outcomes, several stud-
ies have shown that the continuous use of medications after
hospital discharge for acute coronary syndromes was asso-
ciated independently and strongly with lower mortality
(25–27). However, such data in stable CAD patients largely
are lacking.
The limited success of risk factor control, even when
vigorously attempted, suggests that current risk-factor con-
trol approaches have significant limitations that need to be
overcome with new paradigms. For example, one novel
approach to improving adherence based on simplifying
medical regimen complexity is to combine medications
indicated for secondary prevention into one pill. This
concept of a so-called polypill was proposed first by Wald
and Law (28) and consisted of 6 agents (3 blood pressure–
lowering agents from different classes plus aspirin, a statin,
and folic acid). Since then, various different formulations of
polypills have been introduced and are being investigated for
secondary prevention (29,30). Although large-scale ran-
domized trials have not yet been completed to evaluate the
advantages of combining guideline-based agents for second-
ary prevention, a study of patients with CAD, diabetes, or
the 3 Trialsd 1 Year in the 3 Trials
BARI 2D FREEDOM
r
2)
Baseline
(n  2,368)
1 Year
(n  2,142)
Baseline
(n  1,900) 1 Year
29 96 33 86 28 93 36 83 34
19 132 20 128 16 134 20 134 19
1.6 7.7 1.6 7.2 1.4 7.8 1.7 7.4 1.6
17) 12 (11–14) 10 (9–11) 16 (14–17) 6 (5–8)
1 Year
BARI 2D FREEDOM
ear
764)
Baseline
(n  2,368)
1 Year
(n  2,142)
Baseline
(n  1,900) 1 Year
7 59 75 34 42
9 49 56 40 38
8 40 51 37 45
6 88 90 84 94
8 14 23 4 8ar inne an
M
1 Yea
n  67
83
30
7.4
4 (11–Over
DM
1 Y
(n 
7
4
4
8
10 mg/dl), SBP: 130 mm Hg, HbA1c: 7.0, and nonsmoking.
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Risk Factor Control for CAD April 16, 2013:1607–15both showed that the use of a simplified regimen of fixed
doses of statin and angiotensin II-converting enzyme inhib-
itors or angiotensin receptor blockers was feasible and
decreased the risk of hospitalizations for ischemic heart
disease or stroke within 1 year (31). Further large-scale
studies evaluating the impact of a polypill intervention on
the attainment of cardiovascular risk factor targets in high-
risk patients are warranted.
Study limitations. Although this study highlights the lim-
ted degree to which complete risk factor control was
chieved in these trials, there are several limitations. It is
onceivable that risk factor values for patients at 1 year were
ear the goal, but had not completely reached the target.
Figure 1 Percentage of Patients Achieving Target LDL-C Levels A
The COURAGE trial was divided into diabetes (DM) and nondiabetes (NDM) cohort
COURAGE and BARI 2D and 70 mg/dl for FREEDOM.
Figure 2 Percentage of Patients Achieving Goal Values for SBP A
The COURAGE trial was divided into DM and NDM cohorts. Goal systolic blood pre
COURAGE, BARI 2D, and FREEDOM trials. Abbreviations as in Figure 1.Because we used an absolute cutoff for the measure of
control, such borderline patients would not have been
captured by this analysis. This is one plausible explanation
for why the mean values of risk factors in all 3 trials seemed
to be more favorable as compared with the proportion of
patients meeting the targets. Although we acknowledge that
non-high-density lipoprotein cholesterol may be a better
metric for risk in diabetic patients as compared with
LDL-C, we used only targets that were pre-specified by
trial design. Finally, there has been recent debate over the
goal of hypertension control in the elderly age group (older
than 80 years) (32). In our analysis, we used targets and
guidelines that were contemporary to the era of the respec-
the 3 Trials From Baseline to 1 Year of Follow-Up
l low-density lipoprotein cholesterol (LDL-C) was defined as 100 mg/dl for
the 3 Trials From Baseline to 1 Year of Follow-Up
(SBP) was defined as 130 mm Hg for themong
s. Goamong
ssure
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April 16, 2013:1607–15 Risk Factor Control for CADtive trials. The goals were set before the release of this newer
evidence.
The known clinical benefit of risk factor control juxta-
posed with the demonstrated inability to achieve satisfactory
control rates for multiple cardiac risk factors in the ideal
setting of the randomized clinical trial raises the possibility
that a combination of formidable barriers exist. Individually,
these barriers do not seem to be insurmountable, but in the
aggregate, they create fundamental limitations on what
Figure 3 Percentage of Patients Achieving Goal Values for Hem
For the COURAGE trial, only the DM subgroup was analyzed. Target hemoglobin A1c (H
Abbreviations as in Figure 1.
Figure 4 Percentage of Patients Meeting All 4 Targets (LDL-C,
Among the 3 Trials From Baseline to 1 Year of Follow
The COURAGE trial was divided into DM and NDM cohorts. Targets were pre-specified by t
Abbreviations as in Figure 1.optimal risk factor control efforts can achieve. Would
providing more broad-based educational initiatives facilitate
healthcare team adherence to existing clinical practice
guidelines? Would greater attention to each step in the
chain of events that control risk factors (healthcare team
efforts, patient adherence) improve the results? These 3
trials used a multidisciplinary healthcare team approach,
including advanced nurse practitioners, registered dietitians,
and diabetic educators (to varying degrees), but largely were
in A1c Among the 3 Trials From Baseline to 1 Year of Follow-Up
was defined as 7.0% for the COURAGE, BARI 2D, and FREEDOM trials.
, HbA1c, and Smoking Cessation)
included 4 items: LDL-C, SBP, HbA1c, and smoking cessation.oglob
bA1c)SBP
-Up
rial and
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
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risk-factor control.
Conclusions
In 3 major randomized clinical trials of revascularization
strategies where secondary prevention attempts were under-
taken to optimize multiple treatment targets in CAD
patients with diabetes, individual risk factor control was
improved compared with baseline, but the proportion of
patients achieving treatment goals for 4 major cardiac risk
factors (LDL-C, SBP, HbA1c, and smoking cessation) was
limited. These data suggest the possibility of a ceiling effect
on what can be achieved therapeutically in real-world
clinical practice with respect to controlling multiple cardiac
risk factors simultaneously. There is a compelling impera-
tive to explore and define new management paradigms and
novel treatment approaches to optimize risk-factor control
for secondary prevention.
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